Valve-in-Valve Transcatheter Aortic Valve Replacement During Second Trimester of Pregnancy Authors: Aparna Sajja, Maya Dassanayake, Iris Abrahantes Morales, Nanette K Wenger, Clayton Smith, Joe Xie, Patrick Gleason, Adam B Greenbaum, Modele O Ogunniyi Published: 2023 ABSTRACT AbstractCritical bioprosthetic aortic valve stenosis is a rare finding in the second trimester of pregnancy. We present the case of a successful valve-in-valve transcatheter aortic valve replacement in a 16-weeks-pregnant patient. We describe the significant role of the multidisciplinary heart team during preconception and pregnancy.Key Words: aortic stenosis, pregnancy, TAVR, valve-in-valve Case Presentation A 29-year-old gravida 2, para 1 woman with a past medical history of bicuspid aortic stenosis (AS) and bioprosthetic surgical aortic valve replacement (23-mm Perimount, Carpentier-Edwards Perimount Magna Ease) presented at 16 weeks of pregnancy, as a transfer from another hospital, for further management of new-onset decompensated heart failure and severe AS. She had undergone bioprosthetic surgical aortic valve replacement for severe aortic regurgitation with a bicuspid aortic valve 15 years before her current admission. Her prior pregnancy was uncomplicated, and she was induced at 39 weeks and had a cesarean section for an obstetric (OB) indication. She had not seen a cardiologist over the past 5 years, with no imaging of the valve since then. The patient started to develop symptoms of exertional dyspnea before the pregnancy that went unrecognized. Learning Objectives •To understand the role of a multidisciplinary heart team during preconception and pregnancy. To understand the role of a multidisciplinary heart team during preconception and pregnancy. •To recognize the safety and feasibility of performing a rescue TAVR procedure during pregnancy. To recognize the safety and feasibility of performing a rescue TAVR procedure during pregnancy. On admission, her vital signs were as follows: blood pressure was 90/65 mm Hg, heart rate was 93 beats/min, oxygen saturation was 96% on room air, and respiratory rate was 20 breaths/min. Her examination showed jugular venous distension, elevated to the midneck, with a 4/6 systolic murmur more prominent at the right upper sternal border. An S3 gallop was appreciated. Her lungs were clear. Her laboratory data were notable for anemia, with hemoglobin of 10 mg/dL. She had normal renal and liver function test results. Her N-terminal pro–B-type natriuretic peptide was elevated at 855 pg/mL. Echocardiogram showed severely reduced left ventricular systolic function (LVEF) of <20% (Video 1). She had an elevated aortic mean gradient of 56 mm Hg and maximum velocity of 4.7 m/s, with a calculated valve area of 0.41 cm2—consistent with severe AS (Videos 2 and 3). Question 1: What should be the next steps in the workup and management of severe bioprosthetic AS in this pregnant patient? This patient’s care required close multidisciplinary collaboration between the OB, maternal-fetal medicine (MFM), heart failure, and structural cardiology teams. According to the OB and MFM teams, this patient was classified as modified World Health Organization class IV, and pregnancy was strongly contraindicated. She was deemed to have a significantly high risk of maternal morbidity and mortality (estimating more than 50% risk of cardiac complication in pregnancy).1 Despite understanding that this was a high-risk pregnancy, she decided to carry the pregnancy to term. A redo surgical AVR was considered too high risk for the patient and fetus; therefore, transcatheter aortic valve replacement (TAVR) planning was performed. She underwent pre-TAVR computed tomography (CT) imaging, which was discussed with the MFM team and deemed medically necessary. On the TAVR CT, she was noted to have severely calcified aortic valve leaflets, with severely restricted cusp motion. (Video 4, Figure 1). Transcatheter Aortic Valve Replacement Computed Tomography Showing Severely Calcified Aortic Valve Leaflets LC = left cusp; NC = non-coronary cusp; RC = right cusp. During TAVR, the delivery sheath may occlude the iliac artery, depending on the sheath size and anatomy. It is important to note that the uterine artery is a major subbranch of the internal iliac artery. Vascular complications that would require rescue with an aortic occlusion balloon and no blood flow to the placenta, even transiently, could result in fetal demise. However, occlusion of the internal iliac artery has been reported to be generally well tolerated because of contralateral iliac collateral circulation.2 Based on discussions with the patient and OB/MFM, it was recommended that she proceed with management that would be the standard of care in a nongravid patient. Given previable gestational age and severe maternal condition, TAVR was recommended. Question 2: What is the optimal selection and sequence of valve interventions in a young woman: 1) before the childbearing years, and 2) during pregnancy? There is no clear acceptable strategy, with each having its own risks/benefits. Bioprosthetic valves have reduced risk of thromboembolism and avoidance of anticoagulation during pregnancy but are associated with a high risk of structural valve deterioration.3 Prior data have shown that in women with bioprosthetic valves, the rate of reoperation or valve-related death was 82% at 10 years, compared to 29% in those with mechanical valves.4 The patient and heart team must consider future risk and timing of a second surgery when selecting a bioprosthetic valve for younger women. Mechanical valves have shown excellent long-term durability and superior hemodynamic profile; however, they entail the risk of thromboembolism (particularly during pregnancy with the hypercoagulable state) and maternal bleeding.3 They are also associated with increased risk of fetal loss and prematurity, low birth weight, birth defects, and neonatal mortality—attributed to the mandatory use of anticoagulation.3 An alternative to prosthetic valves is the Ross procedure, where the aortic valve is replaced using the patient’s own pulmonic valve with a “pulmonary autograft,” and the coronaries are reimplanted into the graft. A cadaveric pulmonic valve is placed in the pulmonic position (“pulmonary allograft”). This procedure is not thrombogenic and provides excellent valve hemodynamics and has, therefore, been recommended by investigators as an alternative procedure for aortic valve replacement in young women who wish to become pregnant. The operation, however, may be technically difficult if not performed in a center of excellence, and associated mortality was reported to be up to 13% in earlier studies.5 Question 3: When should intervention be considered during preconception and during pregnancy? More than 50% of patients with severe AS have symptoms before pregnancy and, therefore, an indication for valve replacement, underscoring the need for improved cardiac evaluation and appropriate preconception counseling of patients.6 For women with valvular disease, preconception evaluation is critical. Understanding the severity of valvular disease, the presence of heart failure and related symptoms are important predictors of complications. Exercise stress testing is recommended as an objective assessment of functional capacity in asymptomatic patients. Invasive hemodynamic evaluation can be considered if there are discordant echocardiogram variables. Cardiopulmonary exercise testing is preferred in women with decreased exercise performance. Preconception intervention should be considered in women with AS who desire to become pregnant and meet recommended criteria for intervention. Question 4: What is the role of the heart team evaluation during pregnancy and consideration of valve intervention? It has been estimated that more than 68% of cardiovascular-related maternal mortality is avoidable.7 A multidisciplinary pregnancy heart team involving cardiologists; obstetricians; gynecologists; MFM specialists; radiologists; anesthesiologists; pharmacists; and, in this case, structural cardiologists, heart failure cardiologists, and cardiothoracic surgeons helped navigate the patient’s care. Women with cardiovascular disease should be referred to a dedicated cardio-obstetrics team, particularly for preconception counseling, to improve care and outcomes, both for the mother and the baby. This multidisciplinary heart team’s role is not just limited to the pregnancy period but is critical before pregnancy and in the postpartum period. Women referred to the pregnancy heart team should receive appropriate counseling on maternal and fetal risks as well as the potential teratogenic effects of medications and radiation. Radiation doses below 50 mGy are considered safe for fetal exposure. According to the Centers for Disease Control and Prevention, radiation doses between 50 and 100 mGy are considered inconclusive in terms of impact on the fetus.8 A CT scan exposes individuals to 2 to 5 rad (20-50 mGy).9 Radiation exposure should be minimized with high-speed scanning and appropriate shielding. Cardiac magnetic resonance is a safe imaging alternative to CT for TAVR planning during pregnancy. There is uncertainty around the potential effects of gadolinium on the fetus because gadolinium is water soluble and can cross the placenta. Nevertheless, the risks of radiation and iodinated contrast should be weighed against that of gadolinium and be discussed with the patient. Ultimately, the choice of imaging modality may be partly guided by institutional expertise and availability. Furthermore, recently there has been new work using a zero-contrast strategy for performing TAVR that uses echocardiographic guidance as an alternative to aortography. This should be considered in the pregnant patient to avoid intraoperative use of contrast media. This patient underwent successful TAVR with 26-mm EvolutFX (Medtronic) (Videos 5, 6 and 7) with pre-TAVR balloon aortic valvuloplasty using an 18-mm True balloon (Becton Dickinson), with reduction in mean aortic valve gradient from 54 to 10 mm Hg. There was no pos-dilation of the TAVR valve because of the position of the surgical bioprosthetic valve in front of the left main coronary artery. The bioprosthetic aortic valve was well seated and without any aortic regurgitation on the postoperative echocardiogram. The fetal heart rate was normal during and after the procedure. Her echocardiogram at discharge showed improvement in LVEF to 55% to 60%, and the mean aortic gradient was 17 mm Hg. Question 5: What anticoagulants are safe to use in pregnancy? According to the 2020 American College of Cardiology/American Heart Association guidelines for valvular disease, each strategy has maternal and fetal safety advantages and disadvantages.10 For mechanical valves, warfarin during the first trimester is associated with increased risk of fetal loss, teratogenicity (especially >5 mg/d). However, heparin is associated with a higher risk of maternal thrombosis, even though it is safe for the fetus because it does not cross the placenta. Moreover, brief cessation of anticoagulation is required before delivery. Cesarean should be performed for women who go into labor while therapeutically anticoagulated on warfarin because of the risk of fetal hemorrhage with vaginal delivery. For women who have a TAVR bioprosthetic valve, low-dose aspirin is considered safe. There are no adequate randomized controlled trials studying P2Y12 inhibitors during pregnancy or during breastfeeding. Therefore, they are generally not recommended.2 This patient was discharged home on aspirin 162 mg daily after her TAVR. She was closely followed in the clinic and switched to enoxaparin injections 3 months post-TAVR because of concerns about valve thrombosis, with elevated aortic valve gradients (mean gradient of 20 mm Hg and peak gradient of 38 mm Hg), 3 months after the procedure. She had a higher risk of valve thrombosis because of the valve-in-valve nature of the procedure, the underexpanded valve, and the hypercoagulable state during pregnancy. She was advised to stop enoxaparin 1 day before her cesarean. She underwent successful cesarean at 36 weeks 5 days, with delivery of a healthy baby. Her postpartum course was uneventful, and she was restarted on her enoxaparin injections 12 hours later. She underwent a cardiac CT several months later, which demonstrated normal LVEF, with leaflets of the prosthetic aortic valve opening well, but the apparatus is not fully expanded, as shown earlier. Funding Support and Author Disclosures Dr Greenbaum has received proctor honoraria from Medtronic. Dr Ogunniyi has received institutional research grant support from AstraZeneca, Boehringer Ingelheim, Cardurion Pharmaceuticals, and Pfizer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. Appendix For supplemental videos, please see the online version of this paper. Appendix Video 1 Transthoracic Echocardiogram With Severely Reduced LVEF (<20%) in the Parasternal Long-Axis View (PLAX) Video 2 PLAX View, Showing Restricted Opening of the Aortic Valve Video 3 Parasternal Short-Axis (PSAX) View, Showing a Well-Seated Bioprosthetic Valve With Severely Restricted Cusp Mobility Video 4 TAVR CT Showing Calcified Aortic Valve Cusps, With Extremely Limited Opening Video 5 PLAX View, Showing Well-Seated TAVR Valve Inside Bioprosthetic Valve Video 6 PLAX View, With Zoom-In of the TAVR Valve Video 7 PSAX View: Well-Positioned TAVR Valve Inside Bioprosthetic Valve References Associated Data Supplementary Materials Video 1 Transthoracic Echocardiogram With Severely Reduced LVEF (<20%) in the Parasternal Long-Axis View (PLAX) Video 2 PLAX View, Showing Restricted Opening of the Aortic Valve Video 3 Parasternal Short-Axis (PSAX) View, Showing a Well-Seated Bioprosthetic Valve With Severely Restricted Cusp Mobility Video 4 TAVR CT Showing Calcified Aortic Valve Cusps, With Extremely Limited Opening Video 5 PLAX View, Showing Well-Seated TAVR Valve Inside Bioprosthetic Valve Video 6 PLAX View, With Zoom-In of the TAVR Valve Video 7 PSAX View: Well-Positioned TAVR Valve Inside Bioprosthetic Valve